Annual Cash & Cash Equivalents
$2.18 B
+$47.33 M+2.21%
December 31, 2024
Summary
- As of February 7, 2025, NVO annual cash & cash equivalents is $2.18 billion, with the most recent change of +$47.33 million (+2.21%) on December 31, 2024.
- During the last 3 years, NVO annual cash & cash equivalents has risen by +$552.17 million (+33.83%).
- NVO annual cash & cash equivalents is now -28.11% below its all-time high of $3.04 billion, reached on December 31, 2017.
Performance
NVO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$2.18 B
-$6.36 B-74.43%
December 31, 2024
Summary
- As of February 7, 2025, NVO quarterly cash and cash equivalents is $2.18 billion, with the most recent change of -$6.36 billion (-74.43%) on December 31, 2024.
- Over the past year, NVO quarterly cash and cash equivalents has dropped by -$5.40 billion (-71.20%).
- NVO quarterly cash and cash equivalents is now -74.43% below its all-time high of $8.54 billion, reached on September 30, 2024.
Performance
NVO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NVO Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +2.2% | -71.2% |
3 y3 years | +33.8% | +33.8% |
5 y5 years | -5.9% | -5.9% |
NVO Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +33.8% | -74.4% | +138.8% |
5 y | 5-year | -5.9% | +33.8% | -74.4% | +143.8% |
alltime | all time | -28.1% | +1651.5% | -74.4% | +1651.5% |
Novo Nordisk A/S Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $2.18 B(+2.2%) | $2.18 B(-74.4%) |
Sep 2024 | - | $8.54 B(+12.6%) |
Jun 2024 | - | $7.58 B(+728.9%) |
Mar 2024 | - | $914.80 M(-57.2%) |
Dec 2023 | $2.14 B(+17.3%) | $2.14 B(-49.9%) |
Sep 2023 | - | $4.27 B(+35.6%) |
Jun 2023 | - | $3.15 B(+44.0%) |
Mar 2023 | - | $2.19 B(+20.1%) |
Dec 2022 | $1.82 B(+11.6%) | $1.82 B(-51.6%) |
Sep 2022 | - | $3.76 B(+17.7%) |
Jun 2022 | - | $3.20 B(+59.0%) |
Mar 2022 | - | $2.01 B(+23.2%) |
Dec 2021 | $1.63 B(-22.6%) | $1.63 B(-64.5%) |
Sep 2021 | - | $4.60 B(+18.7%) |
Jun 2021 | - | $3.88 B(+332.9%) |
Mar 2021 | - | $895.74 M(-57.5%) |
Dec 2020 | $2.11 B(-9.1%) | $2.11 B(-47.5%) |
Sep 2020 | - | $4.02 B(+7.1%) |
Jun 2020 | - | $3.75 B(+160.2%) |
Mar 2020 | - | $1.44 B(-37.8%) |
Dec 2019 | $2.32 B(-3.2%) | $2.32 B(-15.6%) |
Sep 2019 | - | $2.75 B(+24.8%) |
Jun 2019 | - | $2.20 B(+61.9%) |
Mar 2019 | - | $1.36 B(-43.2%) |
Dec 2018 | $2.40 B(-21.1%) | $2.40 B(-6.1%) |
Sep 2018 | - | $2.55 B(-10.6%) |
Jun 2018 | - | $2.85 B(+64.2%) |
Mar 2018 | - | $1.74 B(-42.8%) |
Dec 2017 | $3.04 B(+14.3%) | $3.04 B(+0.3%) |
Sep 2017 | - | $3.03 B(-7.7%) |
Jun 2017 | - | $3.28 B(+36.2%) |
Mar 2017 | - | $2.41 B(-9.4%) |
Dec 2016 | $2.66 B(+7.2%) | $2.66 B(+21.5%) |
Sep 2016 | - | $2.19 B(+11.1%) |
Jun 2016 | - | $1.97 B(+168.8%) |
Mar 2016 | - | $732.53 M(-70.4%) |
Dec 2015 | $2.48 B(+5.5%) | $2.48 B(+6.1%) |
Sep 2015 | - | $2.34 B(+31.3%) |
Jun 2015 | - | $1.78 B(+105.1%) |
Mar 2015 | - | $867.50 M(-63.1%) |
Dec 2014 | $2.35 B(+18.4%) | $2.35 B(+13.9%) |
Sep 2014 | - | $2.06 B(+125.5%) |
Jun 2014 | - | $914.93 M(+88.2%) |
Mar 2014 | - | $486.10 M(-75.5%) |
Dec 2013 | $1.99 B(-3.0%) | $1.99 B(+16.4%) |
Sep 2013 | - | $1.71 B(+21.0%) |
Jun 2013 | - | $1.41 B(+14.2%) |
Mar 2013 | - | $1.23 B(-39.7%) |
Dec 2012 | $2.05 B(-12.4%) | $2.05 B(-12.3%) |
Sep 2012 | - | $2.33 B(+53.8%) |
Jun 2012 | - | $1.52 B(+0.6%) |
Mar 2012 | - | $1.51 B(-35.4%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2011 | $2.34 B(+9.0%) | $2.34 B(-14.2%) |
Sep 2011 | - | $2.72 B(+11.6%) |
Jun 2011 | - | $2.44 B(+25.2%) |
Mar 2011 | - | $1.95 B(-9.1%) |
Dec 2010 | $2.14 B(-1.3%) | $2.14 B(-5.1%) |
Sep 2010 | - | $2.26 B(+20.8%) |
Jun 2010 | - | $1.87 B(+8.2%) |
Mar 2010 | - | $1.73 B(-20.5%) |
Dec 2009 | $2.17 B(+31.5%) | $2.17 B(+8.0%) |
Sep 2009 | - | $2.01 B(+20.5%) |
Jun 2009 | - | $1.67 B(+16.7%) |
Mar 2009 | - | $1.43 B(-13.4%) |
Dec 2008 | $1.65 B(+75.0%) | $1.65 B(+22.5%) |
Sep 2008 | - | $1.35 B(+5.9%) |
Jun 2008 | - | $1.27 B(+35.7%) |
Mar 2008 | - | $938.43 M(-0.6%) |
Dec 2007 | $944.09 M(+63.1%) | $944.09 M(+18.2%) |
Sep 2007 | - | $798.55 M(+14.7%) |
Jun 2007 | - | $696.00 M(+23.4%) |
Mar 2007 | - | $564.00 M(-2.5%) |
Dec 2006 | $578.67 M(+10.6%) | $578.67 M(-3.9%) |
Sep 2006 | - | $602.00 M(+7.2%) |
Jun 2006 | - | $561.53 M(+11.8%) |
Mar 2006 | - | $502.45 M(-3.9%) |
Dec 2005 | $523.00 M(-16.9%) | $523.00 M(-7.2%) |
Sep 2005 | - | $563.69 M(+41.8%) |
Jun 2005 | - | $397.43 M(-1.7%) |
Mar 2005 | - | $404.23 M(-35.8%) |
Dec 2004 | $629.38 M(+194.1%) | $629.38 M(+27.9%) |
Sep 2004 | - | $492.11 M(+48.8%) |
Jun 2004 | - | $330.64 M(+33.9%) |
Mar 2004 | - | $246.84 M(+15.3%) |
Dec 2003 | $214.01 M(+6.6%) | $214.01 M(+6.6%) |
Dec 2002 | $200.83 M(+2.4%) | $200.83 M(+2.4%) |
Dec 2001 | $196.03 M(+23.3%) | $196.03 M(+23.3%) |
Dec 2000 | $159.01 M(-7.3%) | $159.01 M(-7.3%) |
Dec 1999 | $171.62 M(+37.6%) | $171.62 M(+37.6%) |
Dec 1998 | $124.70 M(-24.3%) | $124.70 M(-24.3%) |
Dec 1997 | $164.71 M(+7.1%) | $164.71 M(+7.1%) |
Dec 1996 | $153.76 M(-71.5%) | $153.76 M(-71.5%) |
Dec 1995 | $540.42 M(-50.8%) | $540.42 M(-50.8%) |
Dec 1994 | $1.10 B(+30.4%) | $1.10 B(+30.4%) |
Dec 1993 | $842.90 M(-9.4%) | $842.90 M(-9.4%) |
Dec 1992 | $930.22 M(-8.9%) | $930.22 M(-8.9%) |
Dec 1991 | $1.02 B(+36.0%) | $1.02 B(+36.0%) |
Dec 1990 | $750.32 M(+68.4%) | $750.32 M(+68.4%) |
Dec 1989 | $445.58 M(+21.6%) | $445.58 M(+21.6%) |
Dec 1988 | $366.29 M(+9.2%) | $366.29 M(+9.2%) |
Dec 1987 | $335.56 M(+23.7%) | $335.56 M(+23.7%) |
Dec 1986 | $271.32 M(+15.6%) | $271.32 M(+15.6%) |
Dec 1985 | $234.75 M(+23.7%) | $234.75 M(+23.7%) |
Dec 1984 | $189.82 M | $189.82 M |
FAQ
- What is Novo Nordisk A/S annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual cash & cash equivalents year-on-year change?
- What is Novo Nordisk A/S quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly cash and cash equivalents year-on-year change?
What is Novo Nordisk A/S annual cash & cash equivalents?
The current annual cash & cash equivalents of NVO is $2.18 B
What is the all time high annual cash & cash equivalents for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual cash & cash equivalents is $3.04 B
What is Novo Nordisk A/S annual cash & cash equivalents year-on-year change?
Over the past year, NVO annual cash & cash equivalents has changed by +$47.33 M (+2.21%)
What is Novo Nordisk A/S quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NVO is $2.18 B
What is the all time high quarterly cash and cash equivalents for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly cash and cash equivalents is $8.54 B
What is Novo Nordisk A/S quarterly cash and cash equivalents year-on-year change?
Over the past year, NVO quarterly cash and cash equivalents has changed by -$5.40 B (-71.20%)